{"id":"abciximab-intracoronary","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Bleeding"},{"rate":"1-2","effect":"Thrombocytopenia"},{"rate":"5-10","effect":"Back pain"},{"rate":"5-10","effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL1201584","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Abciximab binds irreversibly to the glycoprotein IIb/IIIa integrin receptor on platelets, which is the final common pathway for platelet aggregation. By blocking this receptor, it prevents fibrinogen and von Willebrand factor from cross-linking platelets, thereby inhibiting platelet clumping. This mechanism is particularly effective in acute coronary syndromes and during percutaneous coronary intervention to reduce thrombotic complications.","oneSentence":"Abciximab is a chimeric monoclonal antibody that blocks the glycoprotein IIb/IIIa receptor on platelet surfaces, preventing platelet aggregation and thrombus formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:58:34.784Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome undergoing percutaneous coronary intervention"},{"name":"Prevention of ischemic complications in patients undergoing coronary angioplasty"}]},"trialDetails":[{"nctId":"NCT03744000","phase":"NA","title":"Deferred Stenting in Patients With Anterior Wall STEMI","status":"ACTIVE_NOT_RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2018-04-03","conditions":"Acute Myocardial Infarction With ST Elevation, Anterior Wall Myocardial Infarction","enrollment":185},{"nctId":"NCT02324348","phase":"NA","title":"Efficacy and Safety Study of Deferred Stenting in Patients With STEMI","status":"COMPLETED","sponsor":"Korea University Anam Hospital","startDate":"2013-06","conditions":"ST-segment Elevation Myocardial Infarction","enrollment":114},{"nctId":"NCT00271401","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Intracoronary Stenting With or Without Abciximab, an Anti-Platelet Therapy, and Conventional Coronary Angioplasty With Abciximab","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"1996-07","conditions":"Angioplasty, Transluminal, Percutaneous Coronary","enrollment":2399},{"nctId":"NCT02105870","phase":"NA","title":"A Randomized Trial of Intracoronary Reopro to Improve Coronary Microvascular Function","status":"UNKNOWN","sponsor":"University of Melbourne","startDate":"2012-02","conditions":"Myocardial Infarction, Coronary Artery Disease","enrollment":40},{"nctId":"NCT00976521","phase":"NA","title":"The INFUSE - Anterior Myocardial Infarction (AMI) Study","status":"COMPLETED","sponsor":"Atrium Medical Corporation","startDate":"2009-09","conditions":"Acute Anterior Myocardial Infarction","enrollment":452},{"nctId":"NCT00440895","phase":"PHASE4","title":"A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI and Rescue-PCI","status":"COMPLETED","sponsor":"Olivier F. Bertrand","startDate":"2007-02","conditions":"Myocardial Infarction, Ischemia","enrollment":74},{"nctId":"NCT01404507","phase":"PHASE4","title":"Efficacy of Combination of IntraCoronary Bolus Abciximab and Aspiration Thrombectomy in STEMI","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-12","conditions":"Acute Myocardial Infarction","enrollment":40},{"nctId":"NCT00894023","phase":"PHASE3","title":"Intracoronary Abciximab With Clearway Catheter","status":"TERMINATED","sponsor":"Gennaro Sardella","startDate":"2009-06","conditions":"Acute Myocardial Infarction","enrollment":150},{"nctId":"NCT01757457","phase":"PHASE4","title":"Anti-inflammatory Effects of Intracoronary and Intravenous Abciximab Administration During Primary Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Azienda Ospedaliero Universitaria Maggiore della Carita","startDate":"2006-04","conditions":"Myocardial Infarction","enrollment":89},{"nctId":"NCT00590070","phase":"PHASE2, PHASE3","title":"THE REOPEN-AMI STUDY - Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Catholic University of the Sacred Heart","startDate":"2008-01","conditions":"Myocardial Infarction","enrollment":240},{"nctId":"NCT01383785","phase":"PHASE4","title":"Thrombus Aspiration for OcLuded Coronary Artery Enhanced With Distal Injection Of Abciximab","status":"UNKNOWN","sponsor":"Hospital Virgen de la Salud","startDate":"2009-11","conditions":"Myocardial Infarction, Occlusive Thrombus","enrollment":186},{"nctId":"NCT01499407","phase":"PHASE4","title":"Randomized Trial of Standard vs ClearWay-infused Abciximab and Thrombectomy for Myocardial Infarction","status":"UNKNOWN","sponsor":"CLI Foundation","startDate":"2011-12","conditions":"ST-elevation Myocardial Infarction","enrollment":128},{"nctId":"NCT00440778","phase":"PHASE4","title":"A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI","status":"COMPLETED","sponsor":"Laval University","startDate":"2007-02","conditions":"Myocardial Infarction, Ischemia","enrollment":105},{"nctId":"NCT00685464","phase":"NA","title":"Intravenous Versus Intracoronary Use of Abciximab","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2006-01","conditions":"Atherosclerosis, Ischemic Heart Disease","enrollment":355},{"nctId":"NCT00712101","phase":"PHASE3","title":"Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction","status":"COMPLETED","sponsor":"University of Leipzig","startDate":"2008-07","conditions":"ST-elevation Myocardial Infarction","enrollment":1912},{"nctId":"NCT00927615","phase":"NA","title":"Comparison of Intracoronary Versus Intravenous Abciximab in ST-segment Elevation Myocardial Infarction (CICERO)","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2008-09","conditions":"ST-Elevation Myocardial Infarction","enrollment":534},{"nctId":"NCT01080638","phase":"PHASE4","title":"Intracoronary Bolus Only Compared With Intravenous Bolus and 12-hours Infusion of Abciximab in Non-ST Elevation Myocardial Infarction.","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2009-10","conditions":"Myocardial Infarction, Angioplasty","enrollment":150},{"nctId":"NCT00320229","phase":"PHASE4","title":"Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous Regimen","status":"TERMINATED","sponsor":"Azienda Sanitaria Ospedaliera","startDate":"2004-12","conditions":"Coronary Disease, Myocardial Infarction","enrollment":84}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"abciximab intracoronary","genericName":"abciximab intracoronary","companyName":"University of Leipzig","companyId":"university-of-leipzig","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abciximab is a chimeric monoclonal antibody that blocks the glycoprotein IIb/IIIa receptor on platelet surfaces, preventing platelet aggregation and thrombus formation. Used for Acute coronary syndrome undergoing percutaneous coronary intervention, Prevention of ischemic complications in patients undergoing coronary angioplasty.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}